Skip to content

Natural History Study for Patients With Angelman Syndrome

A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in CHR Citadelle Liège : NatHis-Angelman

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06229769
Acronym
NatHisAngelman
Enrollment
30
Registered
2024-01-29
Start date
2021-10-10
Completion date
2028-01-31
Last updated
2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angelman Syndrome

Keywords

Actimyo°, Accelerometry, Daily living

Brief summary

This study is a 9-year natural history study for patients with Angelman syndrome in Belgium (a genetic neurodevelopmental disorder, affecting 500,000 individuals in the world). It includes a 3-year recruitment phase, a 5 year follow-up and a year to analyze the collected data. The investigators plan to include 30 patients with a semi-annual follow-up for 4 years. The investigators will collect relevant retrospective and prospective data using age-standardized scales and questionnaires for functional motor assessments and global developmental assessment.

Detailed description

Patients are seen every six months for five years. In these visits, patient have medical review (general medical examination, neurological examination), vital signs (height, weight, respiratory rate, heart rate, blood pressure), cognitive assessment (Bayley-IV), language assessment and questionaire (Bayley-IV, ORCA), motor assessments (Bayley-IV, FMS, Developmental milestones and HINE), quality of life questionnaire (PedsQL, CGI-CASS) and general development questionnaire (Vineland-II).

Interventions

None listed

Sponsors

Centre Hospitalier Régional de la Citadelle
CollaboratorOTHER
SYSNAV
CollaboratorINDUSTRY
Centre Hospitalier Universitaire de Liege
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Genetically confirmed diagnosis of AS * 0-99 years * Male or Female * Participant's carer is willing to give IC/sign a record of consultation for participation in the study

Exclusion criteria

* comorbidity that could potentially affect the results of the study coexists. This

Design outcomes

Primary

MeasureTime frameDescription
Continuous movement monitoring using ActiMyo®2 yearsTo improve the design of future clinical trials by validating tools of assessment based on their suitability to be used as prognostic measures.
Hammersmith Infant Neurological Examination (HINE - if under 2 years old)2 yearsScale of 8 items to evaluation the mobility in young children, scored 0 (unable) to 4 (able and normal for children age) per items (total raw score from 0 to 32).
Vineland-II2 years11 subscales of items evaluated with Caregivers interview tool for assessing the level of autonomy and adaptation for all ages. Subscales are composed as following (higher scores with better the abilites): 1. Listening and understanding, raw score 0 to 40; 2. Speaking, raw score 0 to 108, 3. Reading and writing, raw score 0 to 54, 4. Self caring, raw score 0 to 82, 5. Home caring, raw score 0 to 48, 6. Community living, raw score 0 to 88, 7. Contact with others, raw score 0 to 76, 8. Play and use your free time, raw score 0 to 62, 9. Adapting, raw score 0 to 60, 10. Gros motor, raw score 0 to 80, 11. Fine motor, raw score 0 to 72,
Observed Reported Communication Assessment (ORCA)2 yearsCaregivers interview of 23 items with subscales to assessing the general communication. This is a qualitative questionnaire.
Bayley-IV gross motor functions2 yearsScale of 58 items of Gross motor (raw score 0 to 116) development evaluation.
Bayley-IV fine motor functions2 yearsScale of 46 items of fine motor scale (raw score 0 to 92) development evaluation.
Bayley-IV Cognitive2 yearsScale of 81 items of cognitive scale development evaluation (raw score 0 to 162).
Bayley-IV Receptive Communication2 yearsScale of 42 items of receptive communication abilities scale in development evaluation (raw score 0 to 84).
Bayley-IV Expressive Communication2 yearsScale of 37 items of expressive communication abilities scale in development evaluation (raw score 0 to 74).
Functional Mobility Scale (FMS)2 yearsScale o 3 items (5, 50 and 500 meters distance of ability to move alone) to classify children's functional mobility, document change over time in the same child and to document change seen following. This scale is scored 1 (moving alone with wheelchair) to 6 (running).
Developmental Milestones2 yearsScale to Evaluate the general gross motor milestones of 6 items global motor ability, from ability to sit without support to walk alone (score by able or not able). .

Secondary

MeasureTime frameDescription
Clinical Global Impression - Improvement - Angelman Syndrome (CGI-I-AS)2 yearsCaregivers interview of quality of life severity and change in patient with Angelman Syndrome since last 7 days and since the last month. Part regarding the severity in last 7 days is composed of 9 items scored 0 (not at all difficult) to 4 (very difficult), raw score is between 0 to 36. Part regarding change in last month is composed of 9 items scored 1 (very much improved) to 7 (very much worse), raw score is between 0 to 63,
Pediatric Quality of Life (PedsQL)2 yearsCaregivers interview of quality of life and family impact in daily life separated in two parts, one regarding the last 7 days and one regarding the last month. Total raw score for each part is on 100 (100 related to no impact to 0 related to a huge impact).

Other

MeasureTime frameDescription
Blood sample collection and DNA extraction and storage1 yearTo create a DNA biobank

Countries

Belgium

Contacts

Primary ContactNoor Benmhammed
Noor.Benmhammed@citadelle.be43217726
Backup ContactTamara Dangouloff, PhD
tamara.dangouloff@uliege.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026